Castle Biosciences, Inc. (CSTL)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09

$32.31-1.37%

Close 2026-09-09 · 1-day change

Standing thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Turnaround

Intact: The reason to own it still holds.

The bull case

Castle Biosciences raised 2026 revenue guidance to $345-355 million. Sales grew about 10% last year. The company aims to improve its operating income and net income. It has a strong product in skin cancer diagnostics.

The bear case

The company is still losing money with negative net income. Operating losses worsened from -$6.8M to -$18.4M recently. Revenue growth may slow or miss targets. Costs remain a big challenge.

What's priced in

The price is about 41% below our fair value near $41. Analysts expect about 10% revenue growth. Our view aligns with this but sees risk in profit improvement.

What has to stay true

Net income moves toward positive territoryImproving
Management ExecutionprimaryNet loss less negative than -$14.52 million · next 4 quarters (qualitative)
Breaks if: Net loss worsens beyond -$14.52 million over next year
Operating income improves from negative levelsIntact
Management ExecutionprimaryOperating loss less negative than -$18.41 million · next 4 quarters (qualitative)
Breaks if: Operating loss worsens beyond -$18.41 million over next year
2026 revenue reaches at least $345 millionIntact
Revenue Growthprimary>= $345 million · FY26 (guidance)

Source: QuarterlyIQ research model· Written 2026-07-08· Health checked 2026-09-09· Version 1· Status: Intact· Reviewed when the evidence changes

This is not a price target or investment advice.

Current Outlook

Week of Sep 5, 2026

A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.

CSTL is navigating a challenging landscape with mixed fundamentals and elevated risk.

What kind of bet this is

This investment represents a turnaround story, as CSTL aims to improve its financial performance after recent losses. The current thesis state reflects a cautious optimism, with management making strides in revenue growth and operational improvements.

What's priced into Castle Biosciences, Inc. (CSTL)

The market appears to have priced in a low expectations gap, indicating that investors are not overly optimistic about CSTL's near-term performance. Valuation is considered cheap compared to peers, but the fundamentals suggest a need for caution.

What the fundamentals likely do

Management is focused on increasing revenue guidance and achieving positive Adjusted EBITDA, which shows a commitment to operational improvement. However, the company remains loss-making, and recent financial performance has been neutral, indicating potential volatility.

What Castle Biosciences, Inc. (CSTL) hinges on

The long-term thesis hinges on CSTL's ability to maintain revenue growth and improve profitability while navigating external pressures like economic conditions and sector performance. Key factors include the performance of sector bellwethers and the company's ability to meet its guidance without cutting expectations.

What changed in the latest read

What changed

The most important moves since the prior daily snapshot.

Short-term · Daily

No material changes since the prior snapshot.

Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified at this time.

as of 2026-09-09

See upcoming information that could change the risk

Review the evidence to watch, what would become a concern, and what would make it less concerning.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.